title: Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET).
abstract: Several recent randomized trials comparing everolimus-eluting stent (EES) and sirolimus-eluting stent (SES) reported similar clinical outcomes. This study was aimed to clarify the differences in the angiographic findings of EES as compared to SES. Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial is a prospective multicenter randomized open-label trial comparing EES with SES in Japan. From February to July 2010, 3197 patients were randomly assigned to receive either EES or SES. Of these, angiographic sub-study enrolled 571 patients (EES 285 patients, SES 286 patients). Angiograms were assessed qualitatively and quantitatively at procedure and at 8-12 months in the independent core angiographic laboratory. Late loss of the proximal edges tended to be greater in the EES group than that in the SES group (0.12 ± 0.49 vs. 0.04 ± 0.43 mm, P = 0.05), although late loss in the other segments was similar between the 2 groups. Edge restenosis was mainly observed in EES group, whereas body restenosis was demonstrated in half of SES group. Stent fracture was observed only in the SES group (1.5 %), and peri-stent contrast staining (PSS) tended to be more frequently observed in the SES group than in the EES group (3.6 and 1.5 %, P = 0.18). Restenotic response in the proximal edge was more prominent in the EES group as compared to the SES group. Abnormal angiographic findings such as stent fracture and PSS tended to be more frequent in the SES group.
authors.affiliation: Department of Cardiology, Teikyo University Hospital, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8606, Japan, PXE00364@nifty.com.
authors.forename: Ken
authors.initials: K
authors.lastname: Kozuma
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kimura
authors.forename: Kazushige
authors.initials: K
authors.lastname: Kadota
authors.forename: Satoru
authors.initials: S
authors.lastname: Suwa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kimura
authors.forename: Masashi
authors.initials: M
authors.lastname: Iwabuchi
authors.forename: Kazuya
authors.initials: K
authors.lastname: Kawai
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Miyazawa
authors.forename: Masaki
authors.initials: M
authors.lastname: Kawamura
authors.forename: Koichi
authors.initials: K
authors.lastname: Nakao
authors.forename: Ryuta
authors.initials: R
authors.lastname: Asano
authors.forename: Takashi
authors.initials: T
authors.lastname: Yamamoto
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Suzuki
authors.forename: Jiro
authors.initials: J
authors.lastname: Aoki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kyono
authors.forename: Gaku
authors.initials: G
authors.lastname: Nakazawa
authors.forename: Kengo
authors.initials: K
authors.lastname: Tanabe
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Morino
authors.forename: Keiichi
authors.initials: K
authors.lastname: Igarashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017023:Coronary Angiography / Q000379:methods*; D023903:Coronary Restenosis / Q000175:diagnosis / Q000517:prevention & control; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus